Venus Remedies has announced that in a development crucial to improving healthcare outcomes in Latin America, leading pharmaceutical company Venus has been awarded an oncology tender by the WHO-backed Pan American Health Organisation (PAHO), the world's oldest international public health agency, for supplying essential cancer drugs to multiple Latin American countries.
Venus Remedies has been awarded a tender by UNICEF for supplying ceftriaxone (1gm), a beta-lactam antibiotic, in dry powder form. Ceftriaxone dry powder is an important drug in Venus Remedies’ extensive antibiotic portfolio. Moreover, ceftriaxone is an important antibiotic globally due to its broad-spectrum activity and effectiveness in treating a variety of serious bacterial infections. The global ceftriaxone market was valued at US$ 1.7 billion in 2021 and is expected to grow at a CAGR of 2.9% from 2022 to 2031 to reach over US$ 2.2 billion by the end of 2031.
The Indian pharma industry is one of the largest and most dynamic in the world, supplying affordable and quality medicines to millions of people globally. However, the industry also faces several challenges like increasing competition, regulatory hurdles, pricing pressures and rising R&D costs. To overcome these challenges and achieve sustainable growth, the pharma industry needs to leverage the power of data science and data analytics, which can provide insights, solutions and innovations across the entire value chain.
Venus Remedies Ltd has been awarded with Rs. 2.50 crore under the Production Linked Incentive (PLI) scheme, which covers balance 25% of the total incentive of Rs.10.00 crores. The initial disbursement of Rs. 7.50 crore was awarded by the Central Government earlier this month.
Venus Remedies, one of India’s leading exporters of generic medicines in critical care segments, has further expanded the reach of its oncology drugs in the Asia Commonwealth of Independent States (CIS) region with marketing authorisations from Ukraine for three cancer drugs, including paclitaxel, oxaliplatin and irinotecan.
Venus Remedies gets marketing authorisations for three cancer drugs from Ukraine
Venus Remedies gets huge global acclaim with UNICEF GMP approval
Building on its international presence in the oncology space, Venus Remedies, a global leader in pharmaceutical innovation, has secured marketing authorisation for docetaxel from Israel and cytarabine from Colombia.
Venus Remedies Limited, a leading fixed-dosage injectable manufacturer, has reached a significant milestone with a marketing authorisation from Azerbaijan for the first time for enoxaparin, an anticoagulant that plays a crucial role in addressing blood clot formation in patients suffering from deep vein thrombosis, acute coronary syndrome, heart attacks and pulmonary embolism.
Venus Remedies granted market authorizations in Saudi Arabia and Philippines